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Background: The EGFR signaling pathway is frequently activated in human ovarian cancer and associated with
poor prognosis. However, inhibition of EGFR signaling in patients with recurrent ovarian cancer has been
disappointing. It remains to be addressed whether ovarian cancer patients could benefit from targeting EGFR
signaling. Here we investigated the mechanisms underlying the resistance to EGFR inhibition in ovarian cancer and
developed a strategy to overcome it.
Results: We found that treatment of human ovarian cancer cells with an EGFR inhibitor, gefitinib, resulted in
increased STAT3 phosphorylation in a dose- and time-dependent manner. Inhibiting STAT3 activation with a small
molecule inhibitor of JAK, an upstream kinase that phosphorylates and activates STAT3, synergistically increased the
anti-tumor activity of gefitinib in vitro. Similar results were obtained when STAT3 or JAK1 expression was knocked
down. In contrast, inhibiting other signaling pathways, such as AKT/mTOR, MEK or SRC, was relatively less effective.
The combined treatment resulted in simultaneous attenuation of multiple survival pathways and increased
inhibition of ERK pathway. In addition, the dual inhibition showed a stronger suppression of xenograft tumor
growth than either single inhibition.
Conclusions: Our findings demonstrate that feedback activation of STAT3 pathway might contribute to the
resistance to EGFR inhibition. Combined blockade of both pathways appears to be more effective against human
ovarian cancer than inhibition of each pathway alone both in vitro and in vivo. This study may provide a strategy to
improve clinical benefit of targeting EGFR pathway in ovarian cancer patients.
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Ovarian cancer is the most lethal gynecologic malig-
nancy in the Western world, with more than 21,980 new
cases diagnosed and 14,270 deaths annually in the United
States, according to the American Cancer Society. The
5-year survival rate for ovarian cancer patients ranges
from 30-92%. Although the initial response rate to
standard first line paclitaxel-platinum treatment is over* Correspondence: wwen@coh.org; rjove@vgtifl.org; jyim@coh.org
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unless otherwise stated.70%, most of the patients will eventually experience
recurrence with a median progression-free survival of
18 months. Efforts have been made to overcome
resistance using several classes of chemotherapy agents,
however, mortality remains to be high in the platinum-
resistant patients [1-3]. Therefore, there is a critical
need to develop novel strategies that can be used to
treat advanced and drug resistant ovarian cancer.
Substantial progress has been made in understanding
the molecular events underlying ovarian cancer, which
would facilitate the development of more effectiveis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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naling pathways is persistently activated in human
ovarian cancer, including the epidermal growth factor
receptor (EGFR) and janus kinase/signal transducer and
activator of transcripton 3 (JAK/STAT3) pathways [4].
EGFR is a receptor tyrosine kinase that can be activated
by extracellular ligands, leading to receptor autophos-
phorylation and subsequent activation of downstream
pathways involved in proliferation, survival, angiogenesis,
and invasion [7-9]. In cancer cells, the EGFR pathway is
frequently activated [10-12]. Targeted inhibition of EGFR
with a small molecule kinase inhibitor has been successful
for lung cancer with EGFR mutations [13,14]. The EGF-
receptor is over-expressed in 70% of ovarian cancers and
associated with poor prognosis, suggesting that EGFR is
an attractive therapeutic target in this cancer [12,15-19].
However, clinical trials with several different EGFR inhibi-
tors have shown only modest activity. These trials have
used gefitinib, either as a single agent or in combination
with standard chemotherapy, in patients with recurrent
disease [4,16,20-24]. Studies in non-small cell lung and
other cancers have identified several resistance mecha-
nisms [25-27]. However, little is known about the mech-
anism of resistance in ovarian cancer.
STAT3 is a member of the STAT family of transcrip-
tion factors that mediate cellular responses to cytokines
and growth factors. In normal tissue, STAT3 is latent
and resides in the cytoplasm. In response to cytokine
stimulation, STAT3 is phosphorylated at Tyr705 by JAK.
Phosphorylated STAT3 can then translocate to the nu-
cleus, bind to DNA and activate the transcription of
various genes involved in cell survival and proliferation
[28,29]. In contrast to normal cells, where activation of
STAT3 is tightly regulated and transient, STAT3 is fre-
quently constitutively activated in cancer cells. The
persistent activation of STAT3 could be mediated by
autocrine and/or paracrine cytokine loops through the
JAK family, as well as activation of tyrosine kinases such
as EGFR and SRC [29-32]. Persistent activation of STAT3
plays a critical role in tumor progression by promoting
cell proliferation, cell survival, angiogenesis and tumor im-
mune evasion, and is associated with a poor prognosis for
ovarian cancer patients [29,33-35].
In this study, we investigated the mechanism for the
limited activity of the EGFR inhibitor, gefitinib, in ovar-
ian cancer cells, and found that increased activity of
STAT3 after gefitinib treatment could partially explain
the gefitinib resistance. Inhibition of STAT3 activity with
a JAK inhibitor (JAKi) significantly enhanced the efficacy
of gefitinib against human ovarian cancer cells both
in vitro and in vivo. Our findings indicate that combined
treatment with the EGFR inhibitor, gefitinib, and a JAK/
STAT3 pathway inhibitor could potentially improve ovar-
ian cancer treatment success.Results
Effects of gefitinib on signaling pathways in human
ovarian cancer cells
To study the anti-tumor activity of gefitinib in human
ovarian cancer, we first tested the effects of gefitinib on
the proliferation and viability of SKOV3 and other estab-
lished human ovarian cancer cells. Cells were incubated
with increasing concentrations of gefitinib and cell via-
bility was determined 72 h later. As shown in Figure 1A,
gefitinb inhibited cell viability with IC50s ranging from
3.5 μM to 49 μM. These IC50s are much higher than
the IC50 for sensitive lung cancer cells [36].
It has been suggested that cancer cells often use alter-
native cell survival pathways to overcome growth in-
hibition induced by single drug treatment. In ovarian
cancer cells, many survival pathways are persistently
activated, including AKT, ERK, SRC and STAT3 signaling.
To understand the effect of gefitinib on these signaling
pathways in ovarian cancer cells, SKOV3 and MDAH2774
cells were incubated with increasing concentrations of
gefitinib followed by Western blot analysis. Our results
demonstrated that gefitinib significantly increased phos-
phorylation of STAT3, but not JAK2, in a dose dependent
manner (Figure 1B). As a result of increased pSTAT3, the
expression of MCL-1 and BCL-2, two STAT3 downstream
genes, was also significantly increased in SKOV3 and
MDAH2774, respectively. However, phosphorylation of
ERK and AKT was decreased either in both cell lines
(p-ERK) or only in MDAH2774 (p-AKT). Gefitinib-
induced STAT3 phosphorylation occurred in a time-
dependent manner in SKOV3 cells, reaching a peak at
18 h (Figure 1C). These results suggest that the poten-
tial efficacy of gefitinib in human ovarian cancer cells
might be attenuated by activation of the JAK/STAT3
survival pathway.
Cell viability after combined treatment with gefitinib and
a small molecule inhibitor of the JAK/STAT3 pathway
To understand whether inhibiting JAK/STAT3 pathway
could increase the sensitivity of human ovarian cancer
cells to gefitinib, a recently identified JAKi, AZD1480,
was tested for its effect on cell viability when combined
with gefitinib. This JAKi has been shown to inhibit phos-
phorylation of STAT3 in various cancer cells, including
human ovarian cancer cell lines MDAH2774 and
SKOV3 [37-40]. We treated SKOV3 ovarian cancer cells
with gefitinib either alone or in combination with JAKi.
The combination treatment decreased cell viability much
more robustly than either agent alone (Figure 2A). This
effect was time-dependent with the strongest cytotox-
icity seen at 72 h (Figure 2B). When gefitinib was
combined with JAKi in a fixed 1:1 molar ratio, the con-
centration of gefitinib that gave 50% and 75% inhibition
in SKOV3 cells decreased by about 16 fold from 12 μM
Figure 1 Anti-tumor activity of gefitinib in ovarian cancer cells. (A) Human ovarian cancer cell lines were treated with the indicated
concentrations of gefitinib. Cell viability was determined 72 h later. The IC50 was determined by the Chou-Talalay method. (B) Western blots
showing the dose-dependent effect of gefitinib on downstream signaling in human ovarian cancer cells. SKOV3 and MDAH2774 cells were
incubated with increasing amounts of gefitinib for 24 h. (C) Western blots showing the time-dependent effect of gefitinib on downstream
signaling in SKOV3 cells. SKOV3 cells were incubated with 1 μM gefitinib and collected at the indicated time points. GAPDH and actin were used
as a loading control for SKOV3 and MDAH2774 cells, respectively. Results are representative of 2–5 preparations.
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spectively (Figure 1 and Tables 1 and 2). When fixed
concentrations of JAKi were incubated with increasing
concentrations of the EGFR inhibitor gefitinib, highest
anti-cancer activity was seen in the highest combined
doses (Figure 2C).
To understand whether the increased activity was
additive or synergistic, we determined the combination
index (CI) according to the Chou-Talalay method (CI = 1,
additive effect; CI < 1, synergism; CI > 1 antagonism) [41].
SKOV3 cells were incubated with the combination of
JAKi (fixed at 5 μM) and gefitinib (0.625 to 30 μM) at
various JAKi/gefitinib molar ratios (8:1, 4:1, 2:1, 1:1, 1:2
and 1:3). As shown in Table 1, the combination treatment
produced a very strong synergism at each molar ratio.
But it appears the combination at 1:1 molar ratio produced
stronger synergy and a lower IC50 for both agents in the
SKOV3 cells. We next investigated whether combinationtreatment with gefitinib and JAKi was also more effective
than either agent alone in other human ovarian cancer
cells. As shown in Figure 2D-F and Table 2, mild to very
strong synergy was also observed in other ovarian cell lines,
including OVCAR 8, MDAH2774, and OVCAR3.
Our results thus far indicate that STAT3 inhibition
can enhance the sensitivity of ovarian cancer cells to ge-
fitinib. We next determined whether inhibition of other
pathways such as the AKT/mTOR, MEK/ERK or SRC
pathway would have a similar effect. As shown in Table 3,
inhibition of SRC with saracatinib or MEK with AZD6244
was not able to effectively reduce the IC50 of gefitinib in
SKOV3 cells. An AKT inhibitor, MK2206, or an mTOR
inhibitor, RAD001, synergistically increased gefitinib sen-
sitivity in the ovarian cells, however, was less effective than
JAKi. The concentrations of gefitinib required to induce
75% and 90% inhibition were decreased much more ro-
bustly in the presence of JAKi compared with the other
Figure 2 Suppressing the JAK/STAT3 pathway with a small molecule inhibitor of JAK (JAKi) enhanced the anti-tumor activity of gefitinib in
human ovarian cancer cells. (A) SKOV3 cells were treated with JAKi (AZD1480) or gefitinib alone or in combination at various concentrations in
a fixed molar ratio 1:1. Cell viability was determined 72 h later. (B) SKOV3 cells were treated with JAKi (5 μM) or gefitinb (5 μM) either as single
agent or in combination. Cell viability was determined 24 h, 48 h and 72 h later. (C) SKOV3 cells were incubated with increasing amounts of
gefitinib in the presence of a fixed concentration of JAKi. Cell viability was determined 72 h later. OVCAR8 (D), MDAH2774 (E) and OVCAR 3
cells (F) were treated with gefitinib or JAKi either alone or in combination. Cell viability was determined 72 h later. Results are representative
of 2–5 preparations.
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STAT3 pathway was more effective than inhibiting other
signaling pathways in sensitizing these human ovarian
cancer cells to gefitinib.Effects of combination treatment with gefitinib and JAKi
on apoptosis
Next, we determined whether the synergistic effects of
JAKi and gefitinib extended to induction of apoptosis.
Table 1 Synergistic interaction between JAKi and




Combination index (CI) IC50 (μM)
ED50 ED75 ED90 JAKi Gefitinib
1:3 0.7 0.14 0.052 0.87 2.61
1:2 0.34 0.092 0.044 0.55 1.09
1:1 0.32 0.11 0.048 0.74 0.74
2:1 0.35 0.13 0.061 1.01 0.55
4:1 0.35 0.16 0.08 1.15 0.29
8:1 0.48 0.26 0.15 1.71 0.21
Wen et al. Molecular Cancer  (2015) 14:100 Page 5 of 11Cells were treated with gefitinib and JAKi either alone or
in combination for 48 h and the number of apoptotic
cells was determined by Annexin V staining. As shown
in Figure 3, gefitinib-induced apoptosis increased from
5.7% to 21.8% in SKOV3 cells and from 9.5% to 28.2% in
MDAH2774 cells when combined with JAKi (Figures 3A
and 3C). Consistent with the Annexin V staining results,
more cleaved caspase 3 and cleaved poly-ADP ribose
polymerase (PARP) were generated in the cells that were
treated with both gefitinib and JAKi (Figures 3B and
3D). These results indicate that inhibition of the JAK/
STAT3 pathway could effectively enhance the sensitivity
of these human ovarian cancer cells to gefitinib by pro-
moting apoptosis.
Effect of gefitinib on the viability of cells with JAK/STAT3
knockdown
To further understand whether inhibition of the JAK/
STAT3 pathway could increase the sensitivity of human
ovarian cancer cells to gefitinib, we tested whether gefi-
tinib sensitivity could be enhanced by siRNA-mediated
knockdown of JAK or STAT3. Our previous studies have
shown that depletion of JAK1, but not JAK2, abolished
phosphorylation of STAT3 in SKOV3 and MDAH2774
cells, suggesting that JAK1 is a major kinase responsible
for STAT3 phosphorylation in these two cell lines. We
here examined the sensitivity of ovarian cancer cells to
gefitinib when the JAK/STAT3 pathway was depleted ei-
ther with JAK1 siRNA or STAT3 siRNA. In response to
gefitinib treatment, the number of apoptotic cells signifi-
cantly increased from 17% in cells transfected with aTable 2 Synergistic interaction between JAKi and gefitinib on
cell lines
Cells JAKi: Gefitinib Combination index (CI)
ED50 ED75
SKOV3 1:1 0.32 0.11
MDAH2774 1:2 0.36 0.41
OVCAR 3 1:4 0.29 0.29
OVCAR 8 1:2 0.69 0.57control siRNA to 35% or 41% in cells transfected with
siRNA against JAK1 or STAT3, respectively (Figure 3E).
This result further demonstrates that inhibition of JAK/
STAT3 pathway is an effective way to enhance gefitinib
activity in ovarian cancer.
Similarly, we also investigated whether knockdown of
EGFR expression could increase JAKi-induced apoptosis.
As shown in Figure 3F, JAKi-induced apoptosis in-
creased from 21% to 36% when cells were transfected
with EGFR siRNA, suggesting that inhibition of EGFR
potentiate the inhibitory activity of JAKi in ovarian
cancer.
Effects of combined gefitinib and JAKi treatment on
downstream signaling pathways
To further investigate the synergistic interaction be-
tween gefitinib and JAKi, we evaluated the molecular
changes in ovarian cancer cells after treatment with gefi-
tinib and JAKi either alone or in combination. As shown
in Figure 4, treatment with gefitinib alone resulted in a
decreased level of p-ERK1/2, but not p-STAT3 in both
cell lines at 2 h and 24 h. Treatment with JAKi alone
inhibited p-STAT3 as expected in both cell lines. The
combined treatment with both gefitinib and JAKi led to
inhibition of p-STAT3 (Figure 4), as well as STAT3
downstream genes, MCL-1 and BCL-2 (data not shown).
The inhibition of p-ERK caused by combined treatment
was considerably greater compared to any single treat-
ment in both cell lines. The dual treatment also caused
increased inhibition of p-AKT in both cell lines, al-
though the inhibition was not very strong in SKOV3
cells. A stronger reduction of p-SRC by combination
treatment was also found in MDAH2774 cells. Taken to-
gether, these results demonstrate that combined target-
ing of both, EGFR and JAK/STAT3 pathways, can
inhibit multiple survival pathways and results in greater
inhibition of p-ERK.
Effect of combination treatment on ovarian cancer
growth in mice
Next we investigated whether the combination treat-
ment could suppress tumor growth in vivo more effect-
ively than either treatment alone. NSG mice were
subcutaneously inoculated with SKOV3 ovarian cancercell viability in a variety of human ovarian cancer
Fold reduction (gefitinib)
ED90 IC50 IC75 IC90
0.048 16.13 117.14 1764.86
0.59 5.33 10.92 22.38
0.37 33.11 145.78 645.24
0.47 4.15 6.52 10.23
Table 3 Effects of combining gefitinib with JAK inhibitor (AZD1480), SRC inhibitor (saracatinib), MEK inhibitor
(AZD6244), AKT inhibitor (MK2204) and mTOR inhibitor (RAD001), on the viability of SKOV3 cells
Inhibitor Inhibitor: Gefitinib Combination index (CI) Fold reduction (gefitinib)
ED50 ED75 ED90 IC50 IC75 IC90
JAK 1:1 0.32 0.11 0.048 16.13 117.14 1764.86
SRC 1:3 0.66 0.27 0.11 1.53 3.76 9.28
MEK 1:4 1.09 0.83 0.62 0.95 1.26 1.68
AKT 1:2 0.32 0.35 0.59 6.92 3.51 1.77
mTOR 1:1 0.1 0.22 0.48 10.16 4.6 2.06
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domized into four groups and treated with vehicle con-
trol, gefitinib, JAKi or gefitinib plus JAKi through oral
gavage. No toxicity was observed in mice with any of
the treatments, whether the drugs were used alone or in
combination, as indicated by absence of significant
(>5%) change in body weight (not shown). Treatment
with gefitinib alone was not very effective; the tumor
volume was similar to the vehicle-treated group
(Figure 5A). Treatment with JAKi alone at a daily dose
of 30 mg/kg decreased the tumor burden by 37%. How-
ever, the combination treatment further decreased the
tumor volume by another 22% (Figure 5A), suggesting
that the combination treatment was more effective
than any single treatment.
To investigate molecular changes in the tumors upon
treatment, tumor tissue lysates were analyzed for the ex-
pression of p-EGFR, p-STAT3 and p-ERK by Western
blot analysis. As shown in Figure 5B and 5C, phosphor-
ylation of STAT3 was blocked in the presence of JAKi
either alone or in combination with gefitinib. Combin-
ation of gefitinib with JAKi treatment led to greater in-
hibition of p-ERK, which was consistent with in vitro
results shown in Figure 4. Overall, these results support
a consistent synergistic effect of EGFR and JAK/STAT3
inhibition on ovarian cancer cell growth and survival
both in vitro and in vivo and a potential role for multiple
survival pathways in this effect.
Discussion
To improve the clinical benefit of targeting EGFR in the
treatment of ovarian cancer, we investigated the mech-
anism of resistance to EGFR inhibition. We demonstrate,
for the first time, that inhibition of EGFR significantly
increased phosphorylation of STAT3 in ovarian cancer
cells and blocking STAT3 activation led to enhanced
anti-tumor activity of gefitinib both in vitro and in vivo.
Studies in non-small cell lung cancer and other can-
cers have found that resistance to anti-EGFR agents is
common and occurs through several proposed mecha-
nisms, such as de novo resistance due to genetic alter-
ation of receptors or downstream signaling molecules
and acquired resistance due to activation of alternativesignaling pathways [25-27,36]. However, little is known
about the relevance of these mechanisms to ovarian can-
cer. Unlike non-small cell lung cancer, mutations in
ovarian cancer are rare [23,42,43]. The concurrent acti-
vation of multiple signaling pathways, including EGFR,
PI3/AKT, MEK/ERK and JAK/STAT3, appears to be
more common in ovarian cancer and raises an important
question about the involvement of these signaling path-
ways in the development of drug resistance [4]. Target-
ing the PI3K/AKT/mTOR pathway has been shown to
increase anti-tumor activity of inhibiting EGFR [44,45].
In the present study, we found that inhibition of EGFR
in ovarian cancer cells increased phosphorylation of
STAT3 in both SKOV3 and MDAH2774 cells in a time-
and dose-dependent manner. Blockade of STAT3 pathway
synergistically increased anti-tumor activity of gefitinib, as
well as another EGFR inhibitor (erlotinib) (data not
shown). This finding is consistent with previous reports in
some other tumors, including glioma, lung and pancreatic
cancer [46-49]. Blocking other survival pathways, such as
AKT, mTOR, ERK and SRC, also enhanced the sensitivity
to gefitinib in our study, however, inhibition of these path-
ways was not as effective as inhibiting JAK. Relative to the
other pathways considered in this study, targeting STAT3
appeared to be the most effective way to increase the
therapeutic efficacy of anti-EGFR therapy in these ovarian
cancer cells. Taken together, these results provide a mo-
lecular mechanism underlying resistance to EGFR inhib-
ition in human ovarian cancer.
The gefitinib-induced pSTAT3 was abolished in the
presence of JAK inhibitor, implying JAK might be in-
volved in the activation of STAT3. Our previous study
has demonstrated that the constitutive phosphorylation
of STAT3 is largely mediated through JAK1 in these
ovarian cancer cells, suggesting a possibility of JAK1 as a
main kinase responsible for activation of STAT3 by EGF
blockade [40]. Since pJAK1 was not detectable by West-
ern blot using currently commercial available antibody
(data not shown) in these cell lines, it remains to be ad-
dressed whether gefitinib also induce phosphorylation
and activation of JAK1. The gefitinib–induced activation
of STAT3 is unlikely a temporal activation as STAT3
remained to be activated through whole treatment. Unlike
Figure 3 Suppressing JAK/STAT3 signaling enhanced gefitinib-induced apoptosis in human ovarian cancer cells. SKOV3 (A&B) and MDAH2774
(C&D) cells were treated with gefitinib, JAKi, either alone or together, for 48 h. Apoptosis was determined by flow cytometry using Annexin V
and PI staining (A&C) or for cleaved poly-ADP ribose polymerase (PARP) and cleaved caspase-3 by Western blot (B&D). **, P < 0.005; ***,
P < 0.005, combination vs. JAKi alone or gefitinib alone. (E) SKOV3 cells were transfected with siRNA against STAT3, JAK1, or control siRNA and
treated with gefitinib or (F) transfected with siRNA against EGFR and treated with JAKi. After 48 h, cells were harvested and evaluated for
apoptosis using Annexin V staining. *, P < 0.05; **, P < 0.005, vs. control siRNA.
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curs at early time, the gefitinib-induced phosphorylation
of STAT3 appeared to be stronger at later points, suggest-
ing that JAK/STAT3 might be activated by gefitinib via an
indirect pathway. Further study is warranted to define themolecular mechanism underlying the activation of STAT3
by gefitinib.
While inhibiting a single pathway including EGFR and
JAK/STAT3 was not sufficient to significantly block cell
growth and survival (Figures 1 and 2), dual blockade of
Figure 4 Western blots show that combination treatment with JAKi
and gefitinib caused attenuation of multiple signaling pathways.
SKOV3 (A) and MDAH2774 (B) cells were treated with JAKi, gefitinib
or the combination for 2 h and 24 h. Results are representative of
2–4 preparations.
Figure 5 JAKi increased the anti-tumor activity of gefitinib in mice.
(A) SKOV3 cells were implanted subcutaneously into the right flank
of nude mice. Tumors were treated with vehicle, JAKi (30 mg/kg),
gefitinib (150 mg/kg) or their combination by oral gavage once daily.
Tumor growth was measured twice a week. Data represents means ± SD
(n = 8-10). *, P < 0.05; ***, P < 0.005, combination vs. vehicle, or gefitinib
alone or JAKi alone. (B) Western blots show the effects of treatment on
the indicated intracellular signaling pathways in tumor tissue. (C) Relative
levels of p-EGFR, p-STAT3, p-ERK were determined by measuring the
density of each band and normalized to that of GAPDH. Densitometry
data were relative changes in protein expression and were mean ± SD of
2–3 preparations. *, P < 0.05; ***, P < 0.0005.
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of multiple survival pathways and dramatically increased
anti-tumor activity in vitro and in vivo. Therefore, con-
current activation of multiple signaling pathways might
be the critical force that drives ovarian cancer cells to
proliferate and survive. To achieve a maximum anti-
tumor activity, simultaneous blockade of multiple sur-
vival pathways may be required. EGFR is one of the
main kinases involved in activation of a number of
downstream survival pathways, such as ERK, AKT and
SRC, in ovarian cancer cells. Inhibition of EGFR couldeffectively increase anti-tumor activity of agents target-
ing other signaling pathways, such as STAT3 or AKT.
Therefore, blocking the EGFR pathway could be an
Wen et al. Molecular Cancer  (2015) 14:100 Page 9 of 11important strategy to improve the impact of targeted
therapy in ovarian cancer.
While activating EGFR mutations have been known as
predictors for response to anti-EGFR therapy in lung
cancer, STAT3 activation was recently suggested as a po-
tential predictive marker for resistance to anti-EGFR
therapies in patients with mCRC and NSCLC, given the
correlation between the activation of STAT3 and resist-
ance of cells to anti-EGFR therapy [50,51]. Further stud-
ies are required to address whether p-STAT3 could be a
potential biomarker to predict the response to gefitinib
in ovarian cancer.
Conclusions
In this study, our results, for the first time, demonstrate
that feedback activation of STAT3 might explain in part
why gefitinib is not effective against human ovarian can-
cer. Combining EGFR blockade with suppression of
JAK/STAT3 signaling is more effective in inhibiting
ovarian cancer growth than inhibition of either pathway
alone. This study may provide a potential combination




JAKi, AZD1480, was kindly provided by AstraZeneca.
Antibodies against p-STAT3 (Y705), STAT3, p-ERK
(T202/Y204) , ERK, p-AKT (S473), p-SRC (Y416), SRC,
p-EGFR (Y1068), EGFR, p-JAK2 (Y1007/1008), JAK2,
BCL-2, PARP, Caspase 3 and GAPDH were obtained
from Cell Signaling Technology (Danvers, MA). The
antibodies against AKT and MCL-1 were from Santa
Cruz Biotechnology (Dallas, TX). The antibody against
actin was from Sigma (St. Louis, MO).
Cell viability assays
Cells (4000 per well for most cells, 7000 per well for
MDAH2774) were plated in 96-well plate format in
100 μl growth medium. Cells were treated with DMSO
or drugs the next day at the indicated concentrations
and incubated for an additional 1 to 3 days. Viable cells
were determined either by the MTS assay (Promega,
Madison, WI, USA) or the acid phosphatase assay [52].
For the MTS assay, 25 μl MTS solution was added dir-
ectly into each well according to the manufacturer’s in-
structions. For the acid phophatase assay, all the media
was removed and p-nitrophenyl phosphate substrate
(10 mM 100 μl) was added into each well and incubated
at 37°C for 45mins. NaOH was added to stop the reac-
tion and the absorbance was read at 415 nM. The IC50
was determined using the Calcusyn software (Biosoft,
Ferguson, MO).Determination of combination index (CI)
The combination index (CI) was determined using the
Chou-Talalay method [41] using the Calcusyn software
(Biosoft, MO).
Annexin V staining
Apoptosis was measured using the Annexin V apoptosis
detection kit (BD bioscience). Briefly, ovarian cancer
cells were treated with gefitinib, JAKi or both com-
pounds. After 48 h, both floating and attached cells were
collected and stained with FITC-Annexin V and PI (pro-
pidium iodide). The staining intensity was then quanti-
fied using fluorescence-activated cell sorting (FACS).
Western blot analysis
Western blots were performed as described previously
[53]. Cells were grown in complete medium overnight
and treated with DMSO or drugs at various concentra-
tions for various times. Cells were washed in cold PBS
and lysed in RIPA lysis buffer (Thermo Scientific) con-
taining Halt protease and phosphatase inhibitors (Thermo
Scientific). Proteins were quantified using BCA protein
assay reagent (Thermo Scientific). Equal amounts of pro-
tein were separated by SDS-polyacrylamide gel electro-
phoresis, transferred to polyvinylidene fluoride membranes
and incubated with total and phosphorylated protein-
specific antibodies. Binding of the primary antibody was de-
tected using a horseradish peroxidase (HRP)-conjugated
secondary antibody and chemiluminescent substrates
(Thermo Scientific).
Transfection with small interfering RNA (siRNA)
RNAiMAX (Invitrogen) was used to transfect siRNA,
according to the manufacturer’s instructions. After 24 h
of incubation with RNAi (Santa Cruz Biotechnology),
cells were treated with drugs as shown.
Animal models
All animal studies were carried out under protocols ap-
proved by the Institutional Animal Care and Use Com-
mittee (IACUC) at City of Hope in accordance with all
applicable federal, state, and local requirements and in-
stitutional guidelines. SKOV3 cells (5×106 in 100 μl)
were inoculated subcutaneously into the right flank of
6- to 8- week-old female NOD/SCID/IL2Rgamma null
(NSG) mice. Once the tumors were palpable, animals
were randomized into groups of 10 to achieve an equal
distribution of tumor sizes in all treatment groups.
Mice were then treated by oral gavage daily with
vehicle, JAKi (30 mg/kg), gefitinib (150 mg/kg), or a
combination of both agents. The doses for these two
drugs were chosen based on previously published stud-
ies [37-39,54]. Tumor volumes were assessed using cal-
ipers twice a week. Tumor volumes were determined
Wen et al. Molecular Cancer  (2015) 14:100 Page 10 of 11using the formula (Width)2 × Length × 0.52. Body weight
was monitored weekly as an indicator of drug-induced
toxicity and overall health of the mice.
Statistical analysis
Data are presented as mean ± S.D. Student’s t-test was
used to compare the means of two groups. All the exper-
iments were repeated 2 to 4 times. P < 0.05 was consid-
ered statistically significant.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and design of study: WW, RJ, JHY; In vitro and in vivo
experiments: WW, JW, LL, YT, MH; Technical and material support: WW, RB,
DAH, ESH, THD; Analysis and interpretation of data: WW, JW, LL, YT, MH, RB,
DAH, ESH, THD, RJ and JHY; Writing, review and/or revision of the
manuscript: WW, RB, DAH, ESH, THD, RJ and JHY. All authors read and
approved the final manuscript.
Grant support
This work was supported by NIH grant R01 CA 115674–05 to R. Jove. The
core facilities used in this study were supported by NCI p30 CA033572.
Acknowledgements
We thank our lab members for their valuable suggestions and discussions,
Dr. Dennis Huszar at AstraZeneca for providing AZD1480, Ms. Yan Wang for
her assistance in the animal studies, and Dr. Nancy Linford for critical reading
of this manuscript. We thank Lucy Brown and the Analytical Cytometry Core,
as well as the Animal Facility for their technical assistance.
Author details
1Department of Molecular Medicine, Beckman Research Institute, City of
Hope Comprehensive Cancer Center, 1500 East Duarte Rd., Duarte, CA 91010,
USA. 2Department of Comparative Medicine, Beckman Research Institute,
City of Hope Comprehensive Cancer Center, 1500 East Duarte Rd., Duarte, CA
91010, USA. 3Department of Surgery, Beckman Research Institute, City of
Hope Comprehensive Cancer Center, 1500 East Duarte Rd., Duarte, CA 91010,
USA. 4Vaccine & Gene Therapy Institute of Florida, 9801 SW Discovery Way,
Port St. Lucie 34987, Florida, USA.
Received: 12 December 2014 Accepted: 10 April 2015
References
1. Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, Brenton JD, et al.
Rethinking ovarian cancer: recommendations for improving outcomes. Nat
Rev Cancer. 2011;11(10):719–25.
2. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29.
3. Cristea M, Han E, Salmon L, Morgan RJ. Practical considerations in ovarian
cancer chemotherapy. Ther Adv Med Oncol. 2010;2(3):175–87.
4. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in
ovarian cancer. Nat Rev Cancer. 2009;9(3):167–81.
5. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new
opportunities for translation. Nat Rev Cancer. 2009;9(6):415–28.
6. Campos SM, Ghosh S. A current review of targeted therapeutics for ovarian
cancer. J Oncol. 2010;2010:149362.
7. Lemmon MA, Schlessinger J. Cell Signaling by Receptor Tyrosine Kinases.
Cell. 2010;141(7):1117–34.
8. Citri A, Yarden Y. EGF–ERBB signalling: towards the systems level. Nat Rev
Mol Cell Biol. 2006;7(7):505–16.
9. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a
model for targeted therapy. Clin Cancer Res. 2006;12(18):5268–72.
10. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev
Mol Cell Biol. 2001;2(2):127–37.
11. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems
biology. Nat Rev Cancer. 2012;12(8):553–63.12. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med.
2008;358(11):1160–74.
13. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of
non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med.
2011;364(10):947–55.
14. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al.
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated
EGFR. N Engl J Med. 2010;362(25):2380–8.
15. Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, et al. Effect of
epidermal growth factor receptor expression level on survival in patients
with epithelial ovarian cancer. Clin Cancer Res. 2005;11(24 Pt 1):8637–43.
16. Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden
L, et al. Targeting the epidermal growth factor receptor in epithelial ovarian
cancer: current knowledge and future challenges. J Oncol.
2010;2010:568938.
17. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P,
et al. The prognostic value of epidermal growth factor receptor mRNA
expression in primary ovarian cancer. Br J Cancer. 1996;73(3):301–6.
18. Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, et al.
EGFR and steroid receptors in ovarian carcinoma: comparison with
prognostic parameters and outcome of patients. Anticancer Res.
1997;17(1B):613–9.
19. Niikura H, Sasano H, Sato S, Yajima A. Expression of epidermal growth
factor-related proteins and epidermal growth factor receptor in common
epithelial ovarian tumors. Int J Gynecol Pathol. 1997;16(1):60–8.
20. Murphy M, Stordal B. Erlotinib or gefitinib for the treatment of relapsed
platinum pretreated non-small cell lung cancer and ovarian cancer:
a systematic review. Drug Resist Updat. 2011;14(3):177–90.
21. Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, et al.
Erlotinib added to carboplatin and paclitaxel as first-line treatment of
ovarian cancer: A phase II study based on surgical reassessment. Gynecol
Oncol. 2010;119(3):451–6.
22. Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in
epithelial ovarian cancer. Br J Cancer. 2011;104(8):1241–5.
23. Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, et al.
Phase II study of gefitinib in patients with relapsed or persistent ovarian or
primary peritoneal carcinoma and evaluation of epidermal growth factor
receptor mutations and immunohistochemical expression: a Gynecologic
Oncology Group Study. Clin Cancer Res. 2005;11(15):5539–48.
24. Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, et al.
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor
(HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian
carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer.
2005;15(5):785–92.
25. Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted
therapies in cancer. Nat Med. 2013;19(11):1389–400.
26. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid
tumours: learning from lung cancer. Nat Rev Clin Oncol.
2014;11(8):473–81.
27. Niederst MJ, Engelman JA. Bypass Mechanisms of Resistance to Receptor
Tyrosine Kinase Inhibition in Lung Cancer. Sci Signal. 2013;6(294):re6.
28. Darnell Jr JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional
activation in response to IFNs and other extracellular signaling proteins.
Science. 1994;264(5164):1415–21.
29. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a
leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809.
30. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C,
et al. Stat3 as an oncogene. Cell. 1999;98(3):295–303.
31. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete
the link. Cancer Cell. 2009;15(2):79–80.
32. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R,
et al. Constitutive activation of Stat3 signaling confers resistance to
apoptosis in human U266 myeloma cells. Immunity. 1999;10(1):105–15.
33. Rosen DG, Mercado-Uribe I, Yang G, Bast RC, Amin HM, Lai R, et al. The role
of constitutively active signal transducer and activator of transcription 3 in
ovarian tumorigenesis and prognosis. Cancer. 2006;107(11):2730–40.
34. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum
evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol.
1997;66(1):27–30.
35. Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8
ascites levels in ovarian cancer patients. BMC Cancer. 2011;11:210.
Wen et al. Molecular Cancer  (2015) 14:100 Page 11 of 1136. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, et al. Acquired
resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by
loss of IGF-binding proteins. J Clin Invest. 2008;118(7):2609–19.
37. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, et al.
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and
oncogenesis in solid tumors. Cancer Cell. 2009;16(6):487–97.
38. Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M, et al. The novel
JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in
suppression of human myeloma cell growth and survival. Leukemia.
2011;25(3):538–50.
39. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, et al.
Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer
Res. 2011;71(21):6601–10.
40. Wen W, Liang W, Wu J, Kowolik CM, Buettner R, Scuto A, et al. Targeting
JAK1/STAT3 signaling suppresses tumor progression and metastasis in a
peritoneal model of human ovarian cancer. Mol Cancer Ther.
2014;13(12):3037–48.
41. Chou TC. Drug combination studies and their synergy quantification using
the Chou-Talalay method. Cancer Res. 2010;70(2):440–6.
42. Lacroix L, Pautier P, Duvillard P, Motte N, Saulnier P, Bidart JM, et al.
Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel
combination is not associated with EGFR kinase domain somatic mutations.
Int J Cancer. 2006;118(4):1068–9.
43. Steffensen KD, Waldstrom M, Olsen DA, Corydon T, Lorentzen KA, Knudsen
HJ, et al. Mutant epidermal growth factor receptor in benign, borderline,
and malignant ovarian tumors. Clin Cancer Res. 2008;14(11):3278–82.
44. Glaysher S, Bolton LM, Johnson P, Atkey N, Dyson M, Torrance C, et al.
Targeting EGFR and PI3K pathways in ovarian cancer. Br J Cancer.
2013;109(7):1786–94.
45. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, et al.
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached
cancer cells. Cancer Cell. 2012;21(2):227–39.
46. Dowlati A, Nethery D, Kern JA. Combined inhibition of epidermal growth
factor receptor and JAK/STAT pathways results in greater growth inhibition
in vitro than single agent therapy. Mol Cancer Ther. 2004;3(4):459–63.
47. Lo HW, Cao X, Zhu H, Ali-Osman F. Constitutively activated STAT3 frequently
coexpresses with epidermal growth factor receptor in high-grade gliomas
and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer
Res. 2008;14(19):6042–54.
48. Jaganathan S, Yue P, Turkson J. Enhanced sensitivity of pancreatic cancer
cells to concurrent inhibition of aberrant signal transducer and activator of
transcription 3 and epidermal growth factor receptor or Src. J Pharmacol
Exp Ther. 2010;333(2):373–81.
49. Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, et al. Targeting
Stat3 Abrogates EGFR Inhibitor Resistance in Cancer. Clin Cancer Res.
2012;18(18):4986–96.
50. Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, et al. Impact of
STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based
therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer.
2013;12(1):28–36.
51. Haura EB, Sommers E, Song L, Chiappori A, Becker A. A pilot study of
preoperative gefitinib for early-stage lung cancer to assess intratumor drug
concentration and pathways mediating primary resistance. J Thorac Oncol.
2010;5(11):1806–14.
52. Yang TT, Sinai P, Kain SR. An acid phosphatase assay for quantifying the
growth of adherent and nonadherent cells. Anal Biochem.
1996;241(1):103–8.
53. Lu J, Zhang K, Nam S, Anderson RA, Jove R, Wen W. Novel angiogenesis
inhibitory activity in cinnamon extract blocks VEGFR2 kinase and
downstream signaling. Carcinogenesis. 2010;31(3):481–8.
54. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic
agents against human tumor xenografts is markedly enhanced by
coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Clin Cancer Res. 2000;6(12):4885–92.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
